Impact News +++ Synbiotic: Tochter muss zum Amtsgericht (4investors) +++ SYNBIOTIC Aktie -4,25%

ELANCO Aktie

>ELANCO Aktienkurs

21.1 EUR (TradegateBSX)

Ask: 21.41 EUR / 280 Stück

Bid: 20.79 EUR / 289 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ELANCO Aktie über LYNX handeln

Intraday

1 Jahr

>ELANCO Performance

1 Woche: +2,6%

1 Monat: +23,6%

3 Monate: -2,0%

6 Monate: +10,0%

1 Jahr: +81,2%

laufendes Jahr: +9,4%

>ELANCO Aktie

Name:

ELANCO ANIMAL HEALTH.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US28414H1032 / A2N6BH

Symbol/ Ticker:

5EA (Frankfurt) / ELAN (NYSE)

Kürzel:

FRA:5EA, ETR:5EA, 5EA:GR, NYSE:ELAN

Index:

Webseite:

https://www.elanco.com/

Profil:

Elanco Animal Health Incorporated is a leading global pharmaceutical company specializing in animal health. Its primary function is the development and delivery of innovative products and solutions to prevent and treat diseases in both companion anim..
>Volltext..

Marktkapitalisierung:

10193.25 Mio. EUR

Unternehmenswert:

13288.53 Mio. EUR

Umsatz:

4269.39 Mio. EUR

EBITDA:

864.7 Mio. EUR

Nettogewinn:

-211.16 Mio. EUR

Gewinn je Aktie:

-0.43 EUR

Schulden:

3482.35 Mio. EUR

Liquide Mittel:

373.45 Mio. EUR

Operativer Cashflow:

503.46 Mio. EUR

Bargeldquote:

0.26

Umsatzwachstum:

3.49%

Gewinnwachstum:

-160.75%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ELANCO

Letzte Datenerhebung:

19.06.26

>ELANCO Kennzahlen

Aktien/ Unternehmen:

Aktien: 499.45 Mio. St.

Frei handelbar: 98.97%

Leerverk. Aktien: 6.64%

Rückkaufquote: -

Mitarbeiter: 9900

Umsatz/Mitarb.: 0.42 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 23.9%

Bewertung:

KGV: -

KGV lG: 22.79

KUV: 2.4

KBV: 1.87

PEG-Ratio: -

EV/EBITDA: 15.37

Rentabilität:

Bruttomarge: 43.76%

Gewinnmarge: -4.95%

Operative Marge: 6.13%

Managementeffizenz:

Gesamtkaprendite: -1.85%

Eigenkaprendite: -3.77%

>ELANCO Peer Group

Gesundheit, Tiermedizin/ Tierbehandlung

>ELANCO Chart & Kurs - NYSE

>ELANCO News

18.06.26 - 13:45	Elanco to launch Elanco Ventures with $25M commitment to back early-stage animal health innovation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

18.06.26 - 13:30	Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health (PR Newswire)
	New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions INDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced plans to establish Elanco Ventures, a dedicated corporate venture......

16.06.26 - 01:06

S&P 500 Set for Best Day Since April as Oil Sinks | The Close 6/15/2026 (Bloomberg)

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Goldman Sachs Chief Equity Strategist & Managing Director Ben Snider, Teneo Global Chair, Political Risk Advisory Kevin Kajiwara, Ariel Investments Chairman, Co-CEO & Chief Investment Officer John Rogers, Kestra Chief Investment Officer Kara Murphy, PIMCO Head of Public Policy Libby Cantrill, Elanco Animal Health CEO Jeff Simmons, & Rapper N.O.R.E & DJ EFN. (Source: Bloomberg)...

16.06.26 - 00:42

Elanco CEO: Screwworm Easier To Manage Than Contain (Bloomberg)

Jeff Simmons, Elanco Animal Health President & CEO, discusses the emerging threat of screwworm infections spreading beyond the initial control zone in Texas, with at least 12 confirmed cases including eight heads of cattle. Simmons reassured viewers that while the pest is expected to spread, it can be managed effectively through current interventions such as the release of sterile flies to reduce the screwworm population. He speaks with Romaine Bostick & Katie Greifeld on "The Close." (Source: Bloomberg)...

15.06.26 - 14:51	Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs (PR Newswire)
	TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine minimizes "pokes" supporting comfortable wellness visits for pets Features proprietary......

04.06.26 - 18:30	Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm (Accesswire)
	Company offers portfolio of treatment options and expert guidance following first confirmed case in the United StatesNew World screwworm has officially reached the United States, with the first con......

03.06.26 - 13:30	New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience (PR Newswire)
	INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry.......

27.05.26 - 18:18	Elanco: Monumental Public-Private Initiative Forms to Permanently Close America′s Protein Gap (Accesswire)
	America's Farmers, Protein Industry, Hunger Advocates Launch $40 Million Initiative to Deliver 3 Billion Protein-Rich Meals Annually NORTHAMPTON, MA / ACCESS Newswire / May 27, 2026 / On the eve of......

20.05.26 - 00:01	Insiderhandel: Vorstand kauft Aktien von Elanco Animal Health im Wert von 99939 USD (Insiderkauf)
	Modi, Rajeev A. - Vorstand - Tag der Transaktion: 2026-05-15...

20.05.26 - 00:01	Insiderhandel: PRESIDENT, CEO AND DIRECTOR kauft Aktien von Elanco Animal Health im Wert von 99843 USD (Insiderkauf)
	Simmons, Jeffrey N. - Vorstand - Tag der Transaktion: 2026-05-15...

18.05.26 - 13:30	Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market (PR Newswire)
	Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight......

12.05.26 - 21:12	Earnings Call Transkript: Elanco übertrifft Prognosen für Q1 2026 mit starkem Wachstum (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.26 - 23:18	Elanco Animal Health Boosts Full Year Forecast (Bloomberg)
	Elanco Animal Health boosted its adjusted earnings per share forecast for the full year. Jeff Simmons, President and CEO at Elanco Animal Health joins Bloomberg Businessweek Daily to discuss their company earnings and how the pet care market is doing. (Source: Bloomberg)...

06.05.26 - 23:48	Elanco outlines 5%-7% organic growth and $1.03-$1.09 adjusted EPS as innovation target rises to $1.2B (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 18:36	Elanco (ELAN) Q1 2026 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 15:48	Starkes Wachstum: Elanco übertrifft im Q1 2026 die Erwartungen und erhöht die Jahresprognose (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 15:33	Elanco Animal Health Reports Q1 2026 Results: Full Earnings Call Transcript (Benzinga)
	Importance Rank: 1 read more...

06.05.26 - 15:15	Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates (Zacks)
	Elanco Animal Health (ELAN) delivered earnings and revenue surprises of +16.28% and +6.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...

06.05.26 - 12:33	Elanco Non-GAAP EPS of $0.40 beats by $0.06, revenue of $1.37B beats by $90M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 12:30	Elanco Animal Health Reports First Quarter 2026 Results (PR Newswire)
	Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target First Quarter 2026 Financial Results: Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growth Reported Net Income of $57 million, Adjusted Net Income of......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Veni, vidi, vici - Ich kam, ich sah, ich siegte. (Caesar über die Schlacht bei Zela gegen Pharnakos II., 47 v. Chr.). - Gajus Julius Caesar

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram